{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T21:08:21Z","timestamp":1785186501421,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,8,17]],"date-time":"2011-08-17T00:00:00Z","timestamp":1313539200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1007\/s11102-011-0339-7","type":"journal-article","created":{"date-parts":[[2011,8,17]],"date-time":"2011-08-17T13:39:11Z","timestamp":1313588351000},"page":"44-49","source":"Crossref","is-referenced-by-count":49,"title":["A comparison of cabergoline and bromocriptine on the risk of valvular heart disease in patients with prolactinomas"],"prefix":"10.1007","volume":"15","author":[{"given":"Cesar Luiz","family":"Boguszewski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Mauricio Correa","family":"dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly Suga","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilian Cassia","family":"Marini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Admar Moraes","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monalisa","family":"Azevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,8,17]]},"reference":[{"key":"339_CR1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2265.2006.02562.x","volume":"65","author":"FF Casanueva","year":"2006","unstructured":"Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R, Fideleff H, Hadani M, Kelly P, Kleinberg D, Laws E, Marek J, Scanlon M, Sobrinho LG, Wass JA, Giustina A (2006) Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 65:265\u2013273","journal-title":"Clin Endocrinol (Oxf)"},{"key":"339_CR2","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"96","author":"S Melmed","year":"2011","unstructured":"Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA, Endocrine Society (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:273\u2013288","journal-title":"J Clin Endocrinol Metab"},{"key":"339_CR3","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s11102-010-0290-z","volume":"14","author":"V Dos Santos Nunes","year":"2011","unstructured":"Dos Santos Nunes V, El Dib R, Boguszewski CL, Nogueira CR (2011) Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis. Pituitary 14:259\u2013265","journal-title":"Pituitary"},{"key":"339_CR4","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","volume":"356","author":"R Zanettini","year":"2007","unstructured":"Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G (2007) Valvular heart disease and the use of dopamine agonists for Parkinson\u2019s disease. N Engl J Med 356:39\u201346","journal-title":"N Engl J Med"},{"key":"339_CR5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa062222","volume":"356","author":"R Schade","year":"2007","unstructured":"Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E (2007) Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356:29\u201338","journal-title":"N Engl J Med"},{"key":"339_CR6","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1056\/NEJMp068265","volume":"356","author":"BL Roth","year":"2007","unstructured":"Roth BL (2007) Drugs and valvular heart disease. N Engl J Med 356:6\u20139","journal-title":"N Engl J Med"},{"key":"339_CR7","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1210\/jc.2009-2095","volume":"95","author":"E Valassi","year":"2010","unstructured":"Valassi E, Klibanski A, Biller BM (2010) Potential cardiac valve effects of dopamine agonists in hyperprolactinemia. J Clin Endocrinol Metab 95:1025\u20131033","journal-title":"J Clin Endocrinol Metab"},{"key":"339_CR8","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/00045415-200211000-00005","volume":"10","author":"J Serratrice","year":"2002","unstructured":"Serratrice J, Disdier P, Habib G, Viallet F, Weiller P (2002) Fibrotic valvular heart disease subsequent to bromocriptine treatment. Cardiol Rev 10:334\u2013336","journal-title":"Cardiol Rev"},{"key":"339_CR9","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/mds.22228","volume":"24","author":"LC Tan","year":"2009","unstructured":"Tan LC, Ng KK, Au WL, Lee RK, Chan YH, Tan NC (2009) Bromocriptine use and the risk of valvular heart disease. Mov Disord 24:344\u2013349","journal-title":"Mov Disord"},{"key":"339_CR10","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/0002-9149(86)90224-9","volume":"57","author":"RB Devereux","year":"1986","unstructured":"Devereux RB, Casale PN, Kligfield P, Eisenberg RR, Miller D, Campo E, Alonso DR (1986) Performance of primary and derived M-mode echocardiographic measurements for detection of left ventricular hypertrophy in necropsied subjects and in patients with systemic hypertension, mitral regurgitation and dilated cardiomyopathy. Am J Cardiol 57:1388\u20131393","journal-title":"Am J Cardiol"},{"key":"339_CR11","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0894-7317(03)00335-3","volume":"16","author":"WA Zoghbi","year":"2003","unstructured":"Zoghbi WA, Enriquez-Sarano M, Foster E, Grayburn PA, Kraft CD, Levine RA, Nihoyannopoulos P, Otto CM, Quinones MA, Rakowski H, Stewart WJ, Waggoner A, Weissman NJ, American Society of Echocardiography (2003) Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 16:777\u2013802","journal-title":"J Am Soc Echocardiogr"},{"key":"339_CR12","doi-asserted-by":"crossref","first-page":"R11","DOI":"10.1530\/EJE-08-0365","volume":"159","author":"A Wakil","year":"2008","unstructured":"Wakil A, Rigby AS, Clark AL, Kallvikbacka-Bennett A, Atkin SL (2008) Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. Eur J Endocrinol 159:R11\u2013R14","journal-title":"Eur J Endocrinol"},{"key":"339_CR13","doi-asserted-by":"crossref","first-page":"672","DOI":"10.4158\/EP.14.6.672","volume":"14","author":"JK Devin","year":"2008","unstructured":"Devin JK, Lakhani VT, Byrd BF 3rd, Blevins LS Jr (2008) Prevalence of valvular heart disease in a cohort of patients taking cabergoline for management of hyperprolactinemia. Endocr Pract 14:672\u2013677","journal-title":"Endocr Pract"},{"key":"339_CR14","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1365-2265.2008.03458.x","volume":"70","author":"N Herring","year":"2009","unstructured":"Herring N, Szmigielski C, Becher H, Karavitaki N, Wass JA (2009) Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clin Endocrinol (Oxf) 70:104\u2013108","journal-title":"Clin Endocrinol (Oxf)"},{"key":"339_CR15","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1365-2265.2009.03608.x","volume":"72","author":"LB Nachtigall","year":"2010","unstructured":"Nachtigall LB, Valassi E, Lo J, McCarty D, Passeri J, Biller BM, Miller KK, Utz A, Grinspoon S, Lawson EA, Klibanski A (2010) Gender effects on cardiac valvular function in hyperprolactinaemic patients receiving cabergoline: a retrospective study. Clin Endocrinol (Oxf) 72:53\u201358","journal-title":"Clin Endocrinol (Oxf)"},{"key":"339_CR16","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1111\/j.1742-1241.2008.01779.x","volume":"62","author":"F Bogazzi","year":"2008","unstructured":"Bogazzi F, Buralli S, Manetti L, Raffaelli V, Cigni T, Lombardi M, Boresi F, Taddei S, Salvetti A, Martino E (2008) Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia. Int J Clin Pract 62:1864\u20131869","journal-title":"Int J Clin Pract"},{"key":"339_CR17","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1210\/jc.2007-2658","volume":"93","author":"M Kars","year":"2008","unstructured":"Kars M, Delgado V, Holman ER, Feelders RA, Smit JW, Romijn JA, Bax JJ, Pereira AM (2008) Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8\u00a0years of dopamine agonist therapy for prolactinoma. J Clin Endocrinol Metab 93:3348\u20133356","journal-title":"J Clin Endocrinol Metab"},{"key":"339_CR18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EJE-08-0213","volume":"159","author":"P Lancellotti","year":"2008","unstructured":"Lancellotti P, Livadariu E, Markov M, Daly AF, Burlacu MC, Betea D, Pierard L, Beckers A (2008) Cabergoline and the risk of valvular lesions in endocrine disease. Eur J Endocrinol 159:1\u20135","journal-title":"Eur J Endocrinol"},{"key":"339_CR19","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11102-008-0134-2","volume":"12","author":"S Vallette","year":"2009","unstructured":"Vallette S, Serri K, Rivera J, Santagata P, Delorme S, Garfield N, Kahtani N, Beauregard H, Aris-Jilwan N, Houde G, Serri O (2009) Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary 12:153\u2013157","journal-title":"Pituitary"},{"key":"339_CR20","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1210\/jc.2007-1403","volume":"93","author":"A Colao","year":"2008","unstructured":"Colao A, Galderisi M, Di Sarno A, Pardo M, Gaccione M, D\u2019Andrea M, Guerra E, Pivonello R, Lerro G, Lombardi G (2008) Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab 93:3777\u20133784","journal-title":"J Clin Endocrinol Metab"},{"key":"339_CR21","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S0002-9149(98)01064-9","volume":"83","author":"JP Singh","year":"1999","unstructured":"Singh JP, Evans JC, Levy D, Larson MG, Freed LA, Fuller DL, Lehman B, Benjamin EJ (1999) Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol 83:897\u2013902","journal-title":"Am J Cardiol"},{"key":"339_CR22","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/mds.20887","volume":"21","author":"C Peralta","year":"2006","unstructured":"Peralta C, Wolf E, Alber H, Seppi K, M\u00fcller S, B\u00f6sch S, Wenning GK, Pachinger O, Poewe W (2006) Valvular heart disease in Parkinson\u2019s disease vs. controls: an echocardiographic study. Mov Disord 21:1109\u20131113","journal-title":"Mov Disord"},{"key":"339_CR23","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1212\/01.wnl.0000238508.68593.1d","volume":"67","author":"M Yamamoto","year":"2006","unstructured":"Yamamoto M, Uesugi T, Nakayama T (2006) Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study. Neurology 67:1225\u20131229","journal-title":"Neurology"},{"key":"339_CR24","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/mds.21225","volume":"22","author":"S Junghanns","year":"2007","unstructured":"Junghanns S, Fuhrmann JT, Simonis G, Oelwein C, Koch R, Strasser RH, Reichmann H, Storch A (2007) Valvular heart disease in Parkinson\u2019s disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study. Mov Disord 22:234\u2013238","journal-title":"Mov Disord"},{"key":"339_CR25","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.clineuro.2007.01.011","volume":"109","author":"G Kenangil","year":"2007","unstructured":"Kenangil G, Ozekmek\u00e7i S, Koldas L, Sahin T, Ergin\u00f6z E (2007) Assessment of valvulopathy in Parkinson\u2019s disease patients on pergolide and\/or cabergoline. Clin Neurol Neurosurg 109:350\u2013353","journal-title":"Clin Neurol Neurosurg"},{"key":"339_CR26","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1365-2796.2007.01874.x","volume":"263","author":"VG Rasmussen","year":"2008","unstructured":"Rasmussen VG, Poulsen SH, Dupont E, \u00d8stergaard K, Safikhany G, Egeblad H (2008) Heart valve disease associated with treatment with ergot-derived dopamine agonists: a clinical and echocardiographic study of patients with Parkinson\u2019s disease. J Intern Med 263:90\u201398","journal-title":"J Intern Med"},{"key":"339_CR27","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/mds.22036","volume":"23","author":"K Yamashiro","year":"2008","unstructured":"Yamashiro K, Komine-Kobayashi M, Hatano T, Urabe T, Mochizuki H, Hattori N, Iwama Y, Daida H, Sakai M, Nakayama T, Mizuno Y (2008) The frequency of cardiac valvular regurgitation in Parkinson\u2019s disease. Mov Disord 23:935\u2013941","journal-title":"Mov Disord"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-011-0339-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11102-011-0339-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-011-0339-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T06:58:32Z","timestamp":1712732312000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11102-011-0339-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,17]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["339"],"URL":"https:\/\/doi.org\/10.1007\/s11102-011-0339-7","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,17]]}}}